跳至主要内容
临床试验/CTRI/2021/09/036392
CTRI/2021/09/036392尚未招募不适用

Comparision of bupivacaine 0.25% and ropivacaine 0.5% in transeversus abdominis plane block for postoperative analgesia in lower segment caesarean section

Dr Hetal N Kanabar1 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2021年9月15日最近更新:

试验速览

阶段
不适用
状态
尚未招募
发起方
入组人数
50
试验地点
1
主要终点
First dose of rescue analgesic will be given when VAS Score more than or equal to 6

研究概览

简要总结

This study is a randomized ,double blind ,parellel group, controlled trial comparing the safety and efficacy of bupivacaine 0.25%  and ropivacaine 0.5% in transeversus abdominis plane block in 50 patients undergoing lower segment caesarean section ,will be conducted at GMERS Medical College, Junagadh. The primary outcome measures will be duration of analgesia that is from the time of giving TAP block to time of giving first rescue analgesic (when VAS Score more than or equal to 6 ). Secondary outcomes will be any local site infection or haematoma, any secondary complications of local anaesthetic agents such as cardiotoxicity or neurotoxicity.

研究设计

研究类型
Interventional
分配方式
Coin toss, Lottery, toss of dice, shuffling cards etc
盲法
Participant and Outcome Assessor Blinded

入排标准

年龄范围
18.00 Year(s) 至 40.00 Year(s)(—)
性别
Female

入选标准

  • ASA physical status 1 or 2, patients giving valid consent, undergoing elective lower segment caesarean section under spinal anaesthesia.

排除标准

  • Known allergy to local anaesthetic agents, patients who are receiving any non-steroidal antiinflammatory drugs or opioids 48 hours prior to surgery, patients with any contraindication to spinal anaesthesia, thrombocytopenia, patients requiring general anaesthesia, local infection at the site of injection.

结局指标

主要结局

First dose of rescue analgesic will be given when VAS Score more than or equal to 6

时间窗: Upto 36 hours after giving TAP block

次要结局

  • Local site infection or haematoma, any secondary complications of local anaesthetic agents such as cardiotoxicity or neurotoxicity(Upto 36 hours after giving TAP block)

研究者

发起方
Dr Hetal N Kanabar
申办方类型
Other [self]

研究点 (1)

Loading locations...

相似试验